HDAC6 and B-cell chronic lymphocytic leukemia: Given the results showing that HDAC6 inhibition relieved CLL T-cell dysfunction in vivo, we rationalized that it may be therapeutically beneficial to combine HDAC6 inhibition with immune checkpoint blockade in CLL in order to augment T-cell mediated antitumor activity.